Skip to main content
Erschienen in: Quality of Life Research 9/2015

01.09.2015

Psychometric evaluation of the EORTC QLQ-PR25 questionnaire in assessing health-related quality of life in prostate cancer survivors: a curate’s egg

verfasst von: Eamonn O’Leary, Frances J. Drummond, Anna Gavin, Heather Kinnear, Linda Sharp

Erschienen in: Quality of Life Research | Ausgabe 9/2015

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

Purpose

The EORTC QLQ-PR25 was primarily developed to measure disease-specific health-related quality of life (HRQoL) of prostate cancer (PCa) patients undergoing active treatment. The growing number of cancer survivors has focussed interest on assessing survivors’ HRQoL. We evaluated psychometric properties of the EORTC QLQ-PR25 questionnaire amongst PCa survivors.

Methods

A postal questionnaire, including the QLQ-PR25, was administered to 6559 PCa survivors 2–18 years post-diagnosis, identified through population-based cancer registries in Ireland; 3348 participated. The QLQ-PR25 has been suggested to have five multi-item subscales measuring urinary (US), bowel (BS) and hormone treatment-related symptoms (TS), sexual activity (SA) and sexual functioning (SF), and a single item measuring bother due to using incontinence aids (IA). Reliability analysis, divergent validity, discriminant validity (compared to EORTC QLQ-C30, DASS-21 and EuroQoL EQ-5D-5L), and exploratory and confirmatory factor analysis (EFA, CFA) were undertaken.

Results

The percentage of survivors completing QLQ-PR25 subscales was: US-79 %; IA-20 %; BS-83 %; TS-86 %; SA-87 %; and SF-26 %. Reliability was acceptable (Cronbach’s α > 0.7) for three subscales (US, SA, SF). The instrument discriminated well between clinically distinct groups, especially those defined by primary treatment(s) and stage at diagnosis. The SA and SF subscales showed good discriminant validity compared to QLQ-C30, DASS-21 and EQ-5D-5L; other subscales did not. EFA reproduced a near fit to the proposed factor structure. CFA confirmed this.

Conclusion

This is the largest ever QLQ-PR25 validation study. When used in PCa survivors, although the proposed factor structure was confirmed, some of the subscales (e.g. BS and TS) showed poor reliability, a lack of discriminant validity and moderate levels of item non-response.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 340 Zeitschriften

aus folgenden Fachgebieten:

  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Versicherung + Risiko




Jetzt Wissensvorsprung sichern!

Literatur
2.
Zurück zum Zitat Jemal, A., Center, M. M., DeSantis, C., & Ward, E. M. (2010). Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiology, Biomarkers and Prevention, 19(8), 1893–1907.PubMedCrossRef Jemal, A., Center, M. M., DeSantis, C., & Ward, E. M. (2010). Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiology, Biomarkers and Prevention, 19(8), 1893–1907.PubMedCrossRef
3.
Zurück zum Zitat De Angelis, R., Sant, M., Coleman, M. P., Francisci, S., Baili, P., Pierannunzio, D., et al. (2014). Cancer survival in Europe 1999–2007 by country and age: Results of EUROCARE-5—a population-based study. The lancet Oncology, 15(1), 23–34.PubMedCrossRef De Angelis, R., Sant, M., Coleman, M. P., Francisci, S., Baili, P., Pierannunzio, D., et al. (2014). Cancer survival in Europe 1999–2007 by country and age: Results of EUROCARE-5—a population-based study. The lancet Oncology, 15(1), 23–34.PubMedCrossRef
4.
Zurück zum Zitat Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., et al. (2012). Cancer treatment and survivorship statistics, 2012. CA: A Cancer Journal for Clinicians, 62(4), 220–241. Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., et al. (2012). Cancer treatment and survivorship statistics, 2012. CA: A Cancer Journal for Clinicians, 62(4), 220–241.
5.
Zurück zum Zitat Sharp, L., Deady, S., Gallagher, P., Molcho, M., Pearce, A., Thomas, A. A., Timmons, A., & Comber, H. (2014). The magnitude and characteristics of the population of cancer survivors: Using population-based estimates of cancer prevalence to inform service planning for survivorship care. BMC Cancer, 14(1), 767. Sharp, L., Deady, S., Gallagher, P., Molcho, M., Pearce, A., Thomas, A. A., Timmons, A., & Comber, H. (2014). The magnitude and characteristics of the population of cancer survivors: Using population-based estimates of cancer prevalence to inform service planning for survivorship care. BMC Cancer, 14(1), 767.
6.
Zurück zum Zitat Bray, F., Ren, J.-S., Masuyer, E., & Ferlay, J. (2013). Global estimates of cancer prevalence for 27 sites in the adult population in 2008. International Journal of Cancer, 132(5), 1133–1145.CrossRef Bray, F., Ren, J.-S., Masuyer, E., & Ferlay, J. (2013). Global estimates of cancer prevalence for 27 sites in the adult population in 2008. International Journal of Cancer, 132(5), 1133–1145.CrossRef
7.
Zurück zum Zitat Rnic, K., Linden, W., Tudor, I., Pullmer, R., & Vodermaier, A. (2013). Measuring symptoms in localized prostate cancer: A systematic review of assessment instruments. Prostate Cancer and Prostatic Diseases, 16(2), 111–122.PubMed Rnic, K., Linden, W., Tudor, I., Pullmer, R., & Vodermaier, A. (2013). Measuring symptoms in localized prostate cancer: A systematic review of assessment instruments. Prostate Cancer and Prostatic Diseases, 16(2), 111–122.PubMed
8.
Zurück zum Zitat Van Andel, G., Bottomley, A., Fosså, S. D., Efficace, F., Coens, C., Guerif, S., et al. (2008). An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer. European Journal of Cancer, 44(16), 2418–2424.PubMedCrossRef Van Andel, G., Bottomley, A., Fosså, S. D., Efficace, F., Coens, C., Guerif, S., et al. (2008). An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer. European Journal of Cancer, 44(16), 2418–2424.PubMedCrossRef
9.
Zurück zum Zitat Arraras, J. I., Villafranca, E., Arias de la Vega, F., Romero, P., Rico, M., Vila, M., et al. (2009). The EORTC Quality of Life Questionnaire for patients with prostate cancer: EORTC QLQ-PR25. Validation study for Spanish patients. Clinical and Translational Oncology, 11(3), 160–164.PubMedCrossRef Arraras, J. I., Villafranca, E., Arias de la Vega, F., Romero, P., Rico, M., Vila, M., et al. (2009). The EORTC Quality of Life Questionnaire for patients with prostate cancer: EORTC QLQ-PR25. Validation study for Spanish patients. Clinical and Translational Oncology, 11(3), 160–164.PubMedCrossRef
10.
Zurück zum Zitat Chie, W.-C., Yu, C.-C., & Yu, H.-J. (2010). Reliability and validity of the Taiwan Chinese version of the EORTC QLQ-PR25 in assessing quality of life of prostate cancer patients. Urological Science, 21(3), 118–125.CrossRef Chie, W.-C., Yu, C.-C., & Yu, H.-J. (2010). Reliability and validity of the Taiwan Chinese version of the EORTC QLQ-PR25 in assessing quality of life of prostate cancer patients. Urological Science, 21(3), 118–125.CrossRef
11.
Zurück zum Zitat Chang, Y.-J., Liang, W.-M., Wu, H.-C., Lin, H.-C., Wang, J.-Y., Li, T.-C., et al. (2012). Psychometric evaluation of the Taiwan Chinese version of the EORTC QLQ-PR25 for HRQOL assessment in prostate cancer patients. Health and Quality of Life Outcomes, 10(1), 96.PubMedCentralPubMedCrossRef Chang, Y.-J., Liang, W.-M., Wu, H.-C., Lin, H.-C., Wang, J.-Y., Li, T.-C., et al. (2012). Psychometric evaluation of the Taiwan Chinese version of the EORTC QLQ-PR25 for HRQOL assessment in prostate cancer patients. Health and Quality of Life Outcomes, 10(1), 96.PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Park, J., Shin, D. W., Yun, S. J., Park, S.-W., Jeon, S. S., Kwak, C., et al. (2013). Cross-cultural application of the Korean version of the European Organization for Research and Treatment of Cancer quality of life questionnaire for patients with prostate cancer-EORTC QLQ-PR25. Oncology, 85(5), 299–305.PubMedCrossRef Park, J., Shin, D. W., Yun, S. J., Park, S.-W., Jeon, S. S., Kwak, C., et al. (2013). Cross-cultural application of the Korean version of the European Organization for Research and Treatment of Cancer quality of life questionnaire for patients with prostate cancer-EORTC QLQ-PR25. Oncology, 85(5), 299–305.PubMedCrossRef
13.
Zurück zum Zitat Denham, J. W., Wilcox, C., Lamb, D. S., Spry, N. A., Duchesne, G., Atkinson, C., et al. (2012). Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer. Radiotherapy and Oncology, 105(2), 184–192.PubMedCrossRef Denham, J. W., Wilcox, C., Lamb, D. S., Spry, N. A., Duchesne, G., Atkinson, C., et al. (2012). Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer. Radiotherapy and Oncology, 105(2), 184–192.PubMedCrossRef
14.
Zurück zum Zitat Drummond, F.J., Kinnear, H., O’Leary, E., Donnelly, Gavin, A., & Sharp, L. (2015). Long-term health related quality of life of prostate cancer survivors varies by primary treatment. Results from the PiCTure (Prostate Cancer Treatment, your experience) study. Journal of Cancer Survivorship: Research and Practice. doi:10.1007/s11764-014-0419-6. Drummond, F.J., Kinnear, H., O’Leary, E., Donnelly, Gavin, A., & Sharp, L. (2015). Long-term health related quality of life of prostate cancer survivors varies by primary treatment. Results from the PiCTure (Prostate Cancer Treatment, your experience) study. Journal of Cancer Survivorship: Research and Practice. doi:10.​1007/​s11764-014-0419-6.
15.
Zurück zum Zitat Selli, C., Bjartell, A., Burgos, J., Somerville, M., Palacios, J.-M., Benjamin, L., et al. (2014). Burden of illness in prostate cancer patients with a low-to-moderate risk of progression: A one-year, pan-European observational study. Prostate Cancer, 2014, 1–8.CrossRef Selli, C., Bjartell, A., Burgos, J., Somerville, M., Palacios, J.-M., Benjamin, L., et al. (2014). Burden of illness in prostate cancer patients with a low-to-moderate risk of progression: A one-year, pan-European observational study. Prostate Cancer, 2014, 1–8.CrossRef
17.
Zurück zum Zitat Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376.PubMedCrossRef Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376.PubMedCrossRef
18.
Zurück zum Zitat Lovibond, S. H., & Lovibond, P. F. (1995). Manual for the depression anxiety stress scales (2nd ed.). Sydney: Psychology Foundation. Lovibond, S. H., & Lovibond, P. F. (1995). Manual for the depression anxiety stress scales (2nd ed.). Sydney: Psychology Foundation.
19.
Zurück zum Zitat EuroQol Group. (1990). EuroQol–a new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208.CrossRef EuroQol Group. (1990). EuroQol–a new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208.CrossRef
20.
Zurück zum Zitat Oemar, M., & Janssen, B. (2013). EQ-5D-5L user guide. Rotterdam: EuroQoL Group. Oemar, M., & Janssen, B. (2013). EQ-5D-5L user guide. Rotterdam: EuroQoL Group.
21.
22.
Zurück zum Zitat Nunnally, J. C., & Bernstein, I. H. (1994). Psychometric theory. New York: McGraw-Hill. Nunnally, J. C., & Bernstein, I. H. (1994). Psychometric theory. New York: McGraw-Hill.
23.
Zurück zum Zitat De Camargo Cancela, M., Comber, H., & Sharp, L. (2013). Age remains the major predictor of curative treatment non-receipt for localised prostate cancer: A population-based study. British Journal of Cancer, 109(1), 272–279.PubMedCentralPubMedCrossRef De Camargo Cancela, M., Comber, H., & Sharp, L. (2013). Age remains the major predictor of curative treatment non-receipt for localised prostate cancer: A population-based study. British Journal of Cancer, 109(1), 272–279.PubMedCentralPubMedCrossRef
24.
Zurück zum Zitat Heidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., et al. (2014). EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent—update 2013. European Urology, 65(1), 124–137.PubMedCrossRef Heidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., et al. (2014). EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent—update 2013. European Urology, 65(1), 124–137.PubMedCrossRef
25.
Zurück zum Zitat Wilt, T. J., MacDonald, R., Rutks, I., Shamliyan, T. A., Taylor, B. C., & Kane, R. L. (2008). Systematic review: Comparative effectiveness and harms of treatments for clinically localized prostate cancer. Annals of Internal Medicine, 148(6), 435–448.PubMedCrossRef Wilt, T. J., MacDonald, R., Rutks, I., Shamliyan, T. A., Taylor, B. C., & Kane, R. L. (2008). Systematic review: Comparative effectiveness and harms of treatments for clinically localized prostate cancer. Annals of Internal Medicine, 148(6), 435–448.PubMedCrossRef
26.
Zurück zum Zitat Hu, L., & Bentler, P. M. (1999). Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Structural Equation Modeling: A Multidisciplinary Journal, 6(1), 1–55.CrossRef Hu, L., & Bentler, P. M. (1999). Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Structural Equation Modeling: A Multidisciplinary Journal, 6(1), 1–55.CrossRef
27.
Zurück zum Zitat Thomas, A. A., Timmons, A., Molcho, M., Pearce, A., Gallagher, P., Butow, P., et al. (2014). Quality of life in urban and rural settings: A study of head and neck cancer survivors. Oral Oncology, 50(7), 676–682.PubMedCrossRef Thomas, A. A., Timmons, A., Molcho, M., Pearce, A., Gallagher, P., Butow, P., et al. (2014). Quality of life in urban and rural settings: A study of head and neck cancer survivors. Oral Oncology, 50(7), 676–682.PubMedCrossRef
28.
Zurück zum Zitat Glaser, A. W., Fraser, L. K., Corner, J., Feltbower, R., Morris, E. J. A., Hartwell, G., et al. (2013). Patient-reported outcomes of cancer survivors in England 1–5 years after diagnosis: A cross-sectional survey. BMJ Open, 3(4), E002317. Glaser, A. W., Fraser, L. K., Corner, J., Feltbower, R., Morris, E. J. A., Hartwell, G., et al. (2013). Patient-reported outcomes of cancer survivors in England 1–5 years after diagnosis: A cross-sectional survey. BMJ Open, 3(4), E002317.
Metadaten
Titel
Psychometric evaluation of the EORTC QLQ-PR25 questionnaire in assessing health-related quality of life in prostate cancer survivors: a curate’s egg
verfasst von
Eamonn O’Leary
Frances J. Drummond
Anna Gavin
Heather Kinnear
Linda Sharp
Publikationsdatum
01.09.2015
Verlag
Springer International Publishing
Erschienen in
Quality of Life Research / Ausgabe 9/2015
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-015-0958-y

Weitere Artikel der Ausgabe 9/2015

Quality of Life Research 9/2015 Zur Ausgabe

Premium Partner